American Heart Association Scientific Sessions, November 16–18, 2019 (Philadelphia, USA) The AHA Scientific Sessions event is the annual meeting of the American Heart Association, considered the number one cardiovascular research and education meeting in the world. ISCHEMIA1: The results of this trial in 5179 higher-risk patients with stable ischemic heart disease … [Read more...] about AHA 2019: What you need to know
Electrophysiology
Arrhythmic risk stratification of post-MI patients with preserved ejection fraction identifies high risk subgroup
In patients who have experienced myocardial infarction (MI), a moderately reduced level (≤ 35%) of left-ventricular ejection fraction (LVEF) is indicated as the threshold at which cardiologists should consider an implantable cardioverter-defibrillator (ICD), to reduce the likelihood of sudden cardiac death (SCD). Nonetheless, recent studies have indicated that patients with … [Read more...] about Arrhythmic risk stratification of post-MI patients with preserved ejection fraction identifies high risk subgroup
ACC 2019 – What you need to know
American College of Cardiology Meeting March 16 – 18 , 2019 (New Orleans, LA) HEART FAILURE CardioMEMS PAS trial1: The use of a CardioMEMS sensor (monitoring pulmonary artery pressure) in 1200 heart failure (HF) patients resulted in a 58% reduction in HF-related hospitalization rate in the year following the sensor placement as compared to the previous year. IMAGING … [Read more...] about ACC 2019 – What you need to know
Wearable Cardioverter-Defibrillator could not reduce arrhythmic death after Myocardial Infarction
Patients with myocardial infarction, particularly with a low left ventricular ejection fraction, have a high incidence of sudden cardiac death during the early months after the event. Implantable cardioverter-defibrillators are contraindicated until 40-90 days after myocardial infarction (MI). A wearable device could potentially protect against sudden death during this … [Read more...] about Wearable Cardioverter-Defibrillator could not reduce arrhythmic death after Myocardial Infarction